Mil­len­do braces for deep cuts af­ter its last clin­i­cal ef­fort ends in de­feat and a last search for a way to end things

Turn out the lights, the par­ty is over at Mil­len­do Ther­a­peu­tics.

Nine months af­ter pulling the plug on a piv­otal study of their lead drug, the Ann Ar­bor, MI-based biotech is shut­ter­ing its sole re­main­ing ear­ly-stage study for their NK3R an­tag­o­nist MLE-301. And they’re sound­ing a bleak note, plan­ning some deep cuts for the re­main­ing staff while the board goes about the busi­ness of find­ing a way to gain some val­ue out of this for share­hold­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER